Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

FDA approves Johnson & Johnson's Akeega combo for BRCA2 metastatic prostate cancer after Phase 3 data showed major reductions ...

Johnson & Johnson (J&J) has secured a US label expansion for its next-generation oncology combination, Akeega, in breast ...

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy. For men with prostate cancer treated with ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

SAN FRANCISCO -- Men with high-risk localized prostate cancer lived significantly longer with dose-escalated radiation therapy (RT) plus long-term androgen deprivation therapy (ADT), according to long ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...